ObsEva SA (NASDAQ:OBSV, SIX: OBSN))))), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each. The 20,000,000 new shares, to be issued out of the company’s authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around December 12, 2022. The transaction has been decided to provide the group with additional treasury shares that can be used in the future to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.
Pandologic, A Wholly Owned Subsidiary Of Veritone, Inc. Partners With VONQ, Introduces Job-Level Offering Within VONQ HAPI Job Marketing Platform
PandoLogic, a wholly owned subsidiary of Veritone, Inc. (NASDAQ:VERI) and a leading provider of artificial intelligence (AI) hiring solutions, today shared details of a new strategic partnership with
